Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
volociximab + dacarbazine
- Development stage
- Unknown
- Lead developer
- PDL BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Volociximab + dacarbazine is a combination therapy investigated primarily for the treatment of metastatic melanoma. Volociximab is a chimeric monoclonal antibody (IgG4) that specifically targets and binds to α5β1 integrin, an extracellular matrix receptor involved in angiogenesis, tumor growth, and metastasis. By inhibiting α5β1 integrin, volociximab acts as an angiogenesis inhibitor and antineoplastic agent[6][8]. Dacarbazine is an alkylating agent (purine analog) used as chemotherapy for melanoma, Hodgkin lymphoma, and other cancers; it works by interfering with DNA synthesis and function in rapidly dividing cells[2][4][7]. The combination has been studied in phase 2 clinical trials for patients with metastatic melanoma not previously treated with chemotherapy[1][3].
- Other names
- DTICdacarbazine + volociximab
02
Targets
DNAITGA5:ITGB1 (Integrin α5β1)
Beyond the preview
Go deeper on volociximab + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on volociximab + dacarbazine.